For the quarter ending 2025-09-30, VYGR made $13,365K in revenue. -$27,664K in net income. Net profit margin of -206.99%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue (including from related parties, see note 12) | 13,365 | 5,200 | 6,473 | 24,629 |
| Research and development | 35,866 | 31,330 | 31,526 | 30,241 |
| General and administrative | 8,093 | 10,495 | 9,640 | 8,168 |
| Total operating expenses | 43,959 | 41,825 | 41,166 | 38,409 |
| Operating loss | -30,594 | -36,625 | -34,693 | -13,780 |
| Interest income | 2,385 | 2,831 | 3,291 | 4,579 |
| Other income | 400 | 427 | 418 | 200 |
| Total other income, net | 2,785 | 3,258 | 3,709 | 4,779 |
| Loss before income taxes | -27,809 | -33,367 | -30,984 | -9,001 |
| Income tax provision | 83 | 15 | 37 | 43 |
| Net loss | -27,892 | -33,382 | -31,021 | -9,044 |
| Net unrealized gain on available-for-sale securities | 228 | -22 | 208 | 489 |
| Total other comprehensive income | 228 | -22 | 208 | 489 |
| Comprehensive loss | -27,664 | -33,404 | -30,813 | -8,555 |
| Earnings per share, basic | -0.47 | -0.57 | -0.53 | -0.16 |
| Earnings per share, diluted | -0.47 | -0.57 | -0.53 | -0.16 |
| Weighted average number of shares outstanding, basic | 58,803,015 | 58,666,460 | 58,349,769 | 57,851,110 |
| Weighted average number of shares outstanding, diluted | 58,803,015 | 58,666,460 | 58,349,769 | 57,851,110 |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)